Clinical trials list

ALTG Clinical trials list

Active Trials – Recruiting or in Study Start-Up

The following ALTG trials are recruiting or in the study start-up stage.

Trial  Number Title StatusMore Information
ALTG 16/009
Phase II, single arm trial to assess the efficacy and tolerability for patients with the use of Durvalumab and Tremelimumab with Chemotherapy in metastatic EGFR non-small cell lung cancer (NSCLC) following progression on EGFR tyrosine kinase inhibitors. RecruitingTrial summary
ALTG 13/008
Efficacy of early referral to palliative care for improving quality of life and health care resources following recent diagnosis of advanced thoracic malignancies.RecruitingTrial Summary
ALTG 16/007
A single arm multi-centre translational proof of concept study investigating the safety and efficacy of alternating lorlatinib with crizotinib in a pre-treated advanced ALK-rearranged non-small cell lung cancer population with disease progression on a 2nd generation ALK tyrosine kinase inhibitorRecruitingANZCTR
DREAM3R /ALTG 18/001DREAM3R: DuRvalumab (MEDI4736) with chEmotherapy as first line treAtment in advanced pleural Mesothelioma - A phase 3 Randomised trialIn Development

Trials In Follow Up (closed to recruitment)

Trial Number TitleStatusMore Information
ALTG 16/005
Phase 2 trial of alternating osimertinib with gefitinib in patients with EGFR-T790M mutation positive advanced non-small cell lung cancerClosed to recruitmentTrial Summary
ALTG 14/001
A phase III prospective double-blind placebo-controlled randomized study of adjuvant MEDI4736 in completely resected non-small cell lung cancerClosed to recruitmentTrial Summary
ALTG 15/003
A phase 2 trial of durvalumab with first line chemotherapy in mesothelioma with a safety run inClosed to recruitmentANZCTR
ALTG 14/002
A randomised phase 2 trial of nivolumab and stereotactic ablative body radiotherapy in advanced non-small cell lung cancer progressing after first or second line chemotherapyClosed to recruitmentTrial Summary
ALTG 16/012
Phase II trial to assess the overall survival benefit for patients with the use of Nivolumab and Ipilimumab in limited-stage small cell lung cancer (SCLC) after chemo-radiotherapy Closed to recruitmentTrial Summary
ALTG 15/004
A Randomized Trial of Durvalumab and Tremelimumab +/- Platinum-Based Chemotherapy in Patients With High-Risk, Metastatic (Stage IV) Squamous or Non-Squamous Non-Small Cell Lung Cancer (NSCLC)Closed to recruitmentTrial Summary
ALTG 09/005
TROG 09.02
A Randomised Phase III Trial of Highly Conformal Hypofractionated Image Guided ("Stereotactic") Radiotherapy (HypoRT) Versus Conventionally Fractionated Radiotherapy (ConRT) for Inoperable Early Stage I Non-small Cell Lung Cancer (CHISEL)Closed to recruitment ANZCTR

Cobadged/ Endorsed Trials

The following trials have been endorsed by the ALTG.

Trial Number Title StatusMore Information
ALTG 16/013
Activities and influence of the specialist lung cancer nurseIn development
ALTG 16/011
TROG 16.03
Conventional Care Versus Radioablation (Stereotactic Body Radiotherapy) for Extracranial Oligometastases (CORE)Closed to
ALTG 13/002
Health Related Quality of Life in Malignant MesotheliomaCompletedANZCTR
ALTG 13/004
Do lung cancer patients who receive telephone or on-line support have better wellbeing outcomes than those who receive a booklet only.CompletedANZCTR
ALTG 10/001
TROG 11.03
Randomised phase 3 trial of high dose palliative radiotherapy (HDPRT) vs concurrent chemotherapy and HDPRT (C-HDPRT) in patients with good performance status, locally advanced/ small volume metastatic NSCLC not suitable for radical chemo-radiotherapyClosed to follow upANZCTR
ALTG 13/003
Testing an online resource to promote sexual wellbeing for both patients and their partnersCompletedANZCTR
ALTG 15/001
TROG 13.03
A randomised phase 2 trial to test the feasibility of randomising patients with peripheral stage I NSCLC to either Stereotactic Ablative Radiotherapy (SABR) Or SurgeryIn development
ALTG 13/001
TROG 13.01
Stereotactic Ablative Fractionated Radiotherapy versus Radiosurgery for Oligometastatic Neoplasia to the lung: a randomised phase 2 trialClosed to recruitment
TROG 17.02
A Randomised Phase II Trial of Osimertinib With or Without SRS for EGFR Mutated NSCLC With Brain MetastasesOpen to recruitmentANZCTR

Completed/Closed Trials

Trial  Number Title Publications
ALTG 16/004
A phase 2 study of nivolumab with radiotherapy or nivolumab with ipilimumab in the treatment of small cell lung cancer brain metastasesTerminated. Funding withdrawn.
PA in Lung (PAL)
ALTG 08/001
Physical Activity in Lung cancer patientsAnnals of Oncology, Vol 28, Issue 8, Pages 1889-1897, August 2017
ATLG 12/003
Chemotherapy Utilisation for Malignant MesotheliomaAsia-Pacific Journal of Clinical Oncology, Vol 11, Issue 1, Pages 85–92, March 2015
ALTG 04/001Randomized comparison of first line docetaxel/gemcitabine doublet chemotherapy versus sequential single agent chemotherapyLung Cancer, Vol 49, Supplement 2, Pages S263, July 2005
ALTG 04/003
Maintenance Thalidomide in Mesothelioma PatientsThe Lancet Oncology, Vol 14, No. 6, Pages 543–551, May 2013
ALTG 04/009
Lung Cancer Patient PreferencesLung Cancer, Vol 95, Pages 8-14, May 2016
ALTG 06/003
A randomised, phase III trial of adding nitroglycernin to first line chemotherapy in advanced non-small cell lung cancer.Annals of Oncology, Vol 26, Pages 2280-2286, September 2015
ALTG 09/001
Randomised, double-blind trial of carboplatin and paclitaxel with daily oral cediranib or placebo in patients with advanced non-small cell lung cancerEuropean Journal of Cancer, Vol 50, Issue 4, Pages 706 - 712, March 2014
ALTG 09/002
Dacomitinib compared with placebo in pretreated patients with advanced or metastatic non-small-cell lung cancerThe Lancet Oncology, Vol 15, No. 12, Pages 1379-1388, Nov 2014
ALTG 09/004
A phase II clinical trial of the Vascular Disrupting Agent BNC105P as second line chemotherapy for advanced Malignant Pleural MesotheliomaLung Cancer, Vol 81, Pages 422-427, May 2013
ALTG 10/002A Pilot Study To Develop A Classification Algorithm For Identifying Patients With Adenocarcinoma Of Lung Suitable For Individualized TherapiesStudy completed late 2011
ALTG 10/003Implementing standardised PET procedures for scanning, data collection and reporting in patients with NSCLC across Australia’s ALTG sites: A feasibility study.Study completed late 2011
ALTG 10/004Limiting the functional decline of patients with advanced non-small cell lung cancer.Journal of Thoracic Oncology Vol 7, Issue 9, July 2011
Surveillance in patients with MPM
ALTG 17/001
A prospective single arm phase II trialTerminated. Funding withdrawn.